Integrated patient and tumor genetic testing for individualized cancer therapy.

Hertz, D L; McLeod, H L

Hertz, D L; McLeod, H L.

Afiliación

Hertz DL; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
McLeod HL; DeBartolo Family Personalized Medicine Institute, Division of Population Sciences, Moffitt Cancer Center, Tampa, Florida, USA.

Clin Pharmacol Ther ; 99(2): 143-6, 2016 Feb.

Article en En | MEDLINE | ID: mdl-26537014

RESUMEN

Tumor genome analysis is transforming cancer treatment by enabling identification of specific oncogenic drivers and selection of effective targeted agents. Meanwhile, patient genome analysis is being employed across therapeutic areas to inform selection of appropriate drugs and doses for treatment safety. Integration of patient genome analysis concurrent with preemptive tumor genetic testing will enable oncologists to make informed treatment decisions to select the right dose of the right drug for each patient and their tumor.

Asunto(s)

Pruebas Genéticas/tendencias; Oncología Médica/tendencias; Neoplasias/genética; Neoplasias/terapia; Medicina de Precisión/tendencias; Antineoplásicos/efectos adversos; Antineoplásicos/uso terapéutico; Genoma; Humanos; Oncología Médica/normas; Terapia Molecular Dirigida; Neoplasias/diagnóstico; Medicina de Precisión/normas

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas Genéticas / Medicina de Precisión / Oncología Médica / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google